Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference

2/3/25 4:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) will present at the 45^thAnnual TD Cowen Healthcare Conference on Tuesday, March 4^th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250203221873/en/

Media:

[email protected]

Investor:

[email protected]

Get the next $JNJ alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JNJ

Date	Price Target	Rating	Analyst
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS
10/5/2023	$178.00	Outperform	RBC Capital Mkts

More analyst ratings

$JNJ
Press Releases

Fastest customizable press release news feed in the world

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
Johnson & Johnson (NYSE:JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. View source version on businesswire.com: https://www.businesswire.com/news/home/20250203221873/en/ Media: [email protected] Investor: [email protected]
2/3/25 4:30:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour
Underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour and enhanced treatment standards TORONTO, Jan. 23, 2025 /CNW/ - Johnson & Johnson (NYSE:JNJ) is proud to announce a Canadian first: the publication of a consensus statement titled, "Optimizing the management of psoriasis in patients with skin of colour: a Canadian Delphi consensus." This groundbreaking consensus underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour, offering expert recommendati
1/23/25 8:00:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in autoantibody levels, one of the underlying causes of gMG, by up to 75% over a period of 24 weeks The investigational therapy was recently granted U.S. FDA Priority Review for the treatment of gMG SPRING HOUSE, Pa., Jan. 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody positive (anti-AChR+, anti-MuSK+, anti-LRP4
1/23/25 5:35:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists
1/22/25 8:30:00 AM ET
$BDRX
$JNJ
$SWKH
Biotechnology: Pharmaceutical Preparations
Health Care
Diversified Financial Services
Finance
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Gottardis is the owner of, and has served as a consultant at, Gottardis Biotech LLC, a biopharmaceuticals and research and development consultancy firm, since February 2023. Dr. Gottardi
7/15/24 8:05:00 AM ET
$JNJ
$NKGN
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Sarepta Therapeutics Set to Join S&P MidCap 400
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
5/29/24 5:48:00 PM ET
$JNJ
$SPGI
$SRPT
$SWAV
Biotechnology: Pharmaceutical Preparations
Health Care
Finance: Consumer Services
Finance

Johnson & Johnson Reports Q4 and Full-Year 2024 Results
2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* 2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of $2.04, both include $(0.22) due to acquired IPR&D charges related to V-Wave acquisition 2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9%* and adjusted operational growth of 5.4%*. Operational growth excluding COVID-19 Vaccine of 7.0%* 2024 Full-Year Earnings per share (EPS) of $5.79 and Adjusted EPS of $9.98, both include $(0.67) due to acquired IPR&D charges on various transactions throughout the year Significant pipeline
1/22/25 6:20:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potent
1/13/25 6:32:27 AM ET
$ITCI
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potential
1/13/25 6:30:00 AM ET
$ITCI
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

$JNJ
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 21, 2023 - FDA Roundup: July 21, 2023
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
7/21/23 4:02:23 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
5/5/22 4:51:11 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
8/18/21 1:06:11 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $JNJ

$JNJ SEC Filings

Amendment: Johnson & Johnson filed SEC Form 8-K: Financial Statements and Exhibits

Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 13F-HR filed by Johnson & Johnson

$JNJ Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

$JNJ Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

SEC Form 4 filed by Director Woods Eugene A.

SEC Form 4 filed by Director Hewson Marillyn A

$JNJ Press Releases

Fastest customizable press release news feed in the world